Glyphase M1 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 1000 mg in a sustained-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation ensures a gradual release of metformin, improving gastrointestinal tolerability and enhancing patient compliance through once-daily dosing. Glyphase M1 Forte Tablet SR is suitable for patients requiring dual glycemic control mechanisms to achieve optimal blood sugar regulation. It should be used alongside lifestyle modifications such as diet and exercise. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is recommended during therapy. This combination therapy offers an effective and convenient option for managing type 2 diabetes mellitus, aiming to reduce the risk of diabetes-related complications.